Acute Intermittent Porphyria Management

Primary Specialty Designation

The American Gastroenterological Association recommends that gastroenterology/hepatology serve as the primary managing specialty for acute intermittent porphyria, given its hepatic nature and the need for expertise in managing chronic liver complications, including hepatocellular carcinoma surveillance 1, 2
Acute intermittent porphyria is fundamentally a hepatic disorder involving defects in hepatic heme biosynthesis, requiring expertise in hepatology 1
Definitive curative treatment is liver transplantation, which falls under hepatology/transplant hepatology 1, 4

Neurology consultation is essential for managing neurovisceral manifestations, including acute peripheral neuropathy and encephalopathy with seizures, as more than 50% of patients with recurrent attacks develop chronic neurologic symptoms 3
Nephrology involvement becomes critical as patients develop chronic renal disease and potential end-stage renal disease requiring transplantation, with combined liver-kidney transplantation potentially benefiting patients with both recurrent attacks and end-stage renal disease 5, 4
High-risk obstetrics is mandatory for women with acute intermittent porphyria during pregnancy, given the hormonal triggers and increased attack risk during childbearing years, with pre-conception evaluation specifically recommended 4

The American Association for the Study of Liver Diseases recommends that hepatology/gastroenterology specialists establish the biochemical and genetic diagnosis, classify patients into management subgroups, and coordinate acute attack management with intravenous hemin therapy 1, 5, 6
The American Association for the Study of Liver Diseases also recommends long-term surveillance for hepatocellular carcinoma, chronic kidney disease, and hypertension, as well as determining candidacy for liver transplantation in refractory cases 5, 4, 7
The frequency of follow-up depends on clinical subgroup, with recurrent attack patients requiring close monitoring and sporadic attack patients needing annual follow-up 5, 4

Diagnostic delay is a critical pitfall, with the average time from symptom onset to diagnosis being 15 years in the United States and Europe, and any woman aged 15-50 years with unexplained recurrent severe abdominal pain should be screened for acute intermittent porphyria 1, 3